Live Breaking News & Updates on Schedulei European Union|Page 7

Stay updated with breaking news from Schedulei european union. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Pharmadrug Inc.: PharmaDrug Initiates Preclinical Study of Cepharanthine to Both Broaden Its Cancer Scope and to Streamline Its Strategy for Esophageal Cancer


Pharmadrug Inc.: PharmaDrug Initiates Preclinical Study of Cepharanthine to Both Broaden Its Cancer Scope and to Streamline Its Strategy for Esophageal Cancer
PharmaDrug or the
Company ), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that it has entered into a service agreement with a respected contract research organization (CRO) with deep expertise in preclinical oncology model development and drug testing, to evaluate the Company s patented enteric-coated formulation of Cepharanthine ( PD-001 ) in a broad panel of human cancers.
We are focused on advancing the clinical development of our novel Cepharanthine formulation that not only has significant potential for infectious diseases, but also in select rare forms of cancer with high unmet medical needs, said Daniel Cohen, CEO o ....

United States , Liy Pleiotropic , Wangy Cepharanthine , Daniel Cohen , Nemesb Hemorheological , Clin Hemorheol Microcirc , Newsfile Corp , Schedulei European Union , Pharmadrug Inc , Orphan Drug Designation , Enteric Coated Cepharanthine , Pharmadrug Production Gmbh , Super Smart , Sairiyo Therapeutics , Regarding Forward Looking Information , Intj Mol , ஒன்றுபட்டது மாநிலங்களில் , டேனியல் கோஹன் , ஆர்ஃபந் மருந்து பதவி , அருமை புத்திசாலி , தொடர்பாக முன்னோக்கி பார்க்கிறது தகவல் ,

Pharmadrug Inc.: PharmaDrug Announces First FDA Orphan Drug Designation of DMT for the Prevention of Ischemia-Reperfusion Injury from Organ Transplantation


Pharmadrug Inc.: PharmaDrug Announces First FDA Orphan Drug Designation of DMT for the Prevention of Ischemia-Reperfusion Injury from Organ Transplantation
PharmaDrug or the
Company ), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that the U.S. Food and Drug Administration ( FDA ) has granted Orphan Drug Designation ( ODD ) to dimethyltryptamine ( DMT ) for prevention of ischemia-reperfusion injury ( IRI ) in patients undergoing solid organ transplantation, which includes the liver, kidney, heart and lung, to the Company s wholly-owned subsidiary Sairiyo Therapeutics Inc. The FDA ODD granted is broader than the Company s original application for kidney transplantation, recognizing the pernicious consequences of IRI in all solid organ transplantation. ....

United States , Nemesb Hemorheological , Clin Hemorheol Microcirc , Daniel Cohen , Sairiyo Therapeutics Inc , Newsfile Corp , Schedulei European Union , Pharmadrug Inc , Drug Administration , Transplantation Network , Orphan Drug Designation , Sairiyo Therapeutics , Investigational New Drug , Orphan Drug Act , Drug Application , Pharmadrug Production Gmbh , Super Smart , Regarding Forward Looking Information , ஒன்றுபட்டது மாநிலங்களில் , டேனியல் கோஹன் , மாற்று அறுவை சிகிச்சை வலைப்பின்னல் , ஆர்ஃபந் மருந்து பதவி , ஆர்ஃபந் மருந்து நாடகம் , மருந்து விண்ணப்பம் , அருமை புத்திசாலி , தொடர்பாக முன்னோக்கி பார்க்கிறது தகவல் ,

Pharmadrug Inc.: PharmaDrug Advances Product and Clinical Development of Cepharanthine to Treat Rare Cancers and Infectious Diseases


Pharmadrug Inc.: PharmaDrug Advances Product and Clinical Development of Cepharanthine to Treat Rare Cancers and Infectious Diseases
PharmaDrug or the
Company ), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that the Company has entered into an agreement with Southwest Research Institute® ( SwRI® ), to initiate non-clinical and clinical manufacturing of Cepharanthine for the Company s rare cancer and infectious diseases programs.
In connection with PharmaDrug s recent acquisition of Sairiyo Therapeutics Inc., the Company has secured an exclusive license from SwRI to develop and commercialize a novel oral formulation of Cepharanthine for all fields of use as well as exclusive rights to U.S. Patent: 10,576,077, titled Pharmaceutical Salt forms of Cepharanthine and Tetrandrine . For ....

United States , Japan General , Baden Wüberg , Daniel Cohen , Baillyc Cepharanthine , Sairiyo Therapeutics Inc , Newsfile Corp , Schedulei European Union , Research Institute , Pharmadrug Inc , Health Canada , Southwest Research Institute , Drug Designation , Middle East , Pharmadrug Production Gmbh , Super Smart , Sairiyo Therapeutics , Regarding Forward Looking Information , Drug Repurposing Screens , ஒன்றுபட்டது மாநிலங்களில் , ஜப்பான் ஜநரல் , டேனியல் கோஹன் , ஆராய்ச்சி நிறுவனம் , ஆரோக்கியம் கனடா , தென்மேற்கு ஆராய்ச்சி நிறுவனம் , மருந்து பதவி ,